• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

降低医疗成本的机会:第 3 部分。

Opportunities for cost reduction of medical care: part 3.

机构信息

New York University Medical Center, New York, NY 10282, USA.

出版信息

J Community Health. 2012 Aug;37(4):888-96. doi: 10.1007/s10900-011-9534-8.

DOI:10.1007/s10900-011-9534-8
PMID:22258633
Abstract

The level of health care spending in the United States and other developed nations is rising at a disturbingly rapid rate. However, in the United States, these increases are not justified by superior performance. Rather, most other wealthy countries' inhabitants live longer and suffer from fewer medical problems than the average American. This paper demonstrates the continued abundance of opportunities for substantially reducing health care costs without decreasing the quality of care. In particular, it emphasizes the need to reduce the practice of defensive medicine and to enlarge the cadre of non-specialist physicians who educate future doctors. Such cost-saving opportunities are not rare phenomena but are widely available and offer the United States opportunities to move toward the markedly lower cost levels that have been achieved in other countries.

摘要

美国和其他发达国家的医疗保健支出水平正在以惊人的速度快速上升。然而,在美国,这些增长并没有被优越的表现所证明。相反,大多数其他富裕国家的居民比普通美国人寿命更长,遭受的医疗问题也更少。本文表明,在不降低医疗质量的情况下,仍然有大量机会大幅降低医疗成本。特别是,它强调需要减少防御性医疗的做法,并扩大教育未来医生的非专家医生队伍。这种节省成本的机会并不罕见,而是广泛存在的,为美国提供了向其他国家明显较低的成本水平迈进的机会。

相似文献

1
Opportunities for cost reduction of medical care: part 3.降低医疗成本的机会:第 3 部分。
J Community Health. 2012 Aug;37(4):888-96. doi: 10.1007/s10900-011-9534-8.
2
Low costs of defensive medicine, small savings from tort reform.防御性医疗成本低,侵权改革节省少。
Health Aff (Millwood). 2010 Sep;29(9):1578-84. doi: 10.1377/hlthaff.2010.0146.
3
Further opportunities for cost reduction of medical care.进一步降低医疗成本的机会。
J Community Health. 2010 Dec;35(6):561-71. doi: 10.1007/s10900-010-9253-6.
4
How much does defensive medicine cost?防御性医疗的成本是多少?
J Am Health Policy. 1994 Jul-Aug;4(4):7-15.
5
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
Slowing the growth of health care costs.
N Engl J Med. 2008 Jul 24;359(4):435.
7
We can reduce us health care costs.我们可以降低美国的医疗保健成本。
Am J Med. 2010 Mar;123(3):193-4. doi: 10.1016/j.amjmed.2009.12.011.
8
The prevalence and costs of defensive medicine among orthopaedic trauma surgeons: a national survey study.骨科创伤外科医生中防御性医疗的流行率和成本:一项全国性调查研究。
J Orthop Trauma. 2013 Oct;27(10):592-7. doi: 10.1097/BOT.0b013e31828b7ab4.
9
Slowing the growth of health care costs.减缓医疗保健成本的增长。
N Engl J Med. 2008 Jul 24;359(4):435.
10
Options for slowing the growth of health care costs.减缓医疗保健成本增长的方法。
N Engl J Med. 2008 Apr 3;358(14):1509-14. doi: 10.1056/NEJMsb0707912.

引用本文的文献

1
Defensive medicine through the lens of the managerial perspective: a literature review.从管理视角看防御性医疗:文献综述。
BMC Health Serv Res. 2023 Oct 17;23(1):1104. doi: 10.1186/s12913-023-10089-3.
2
National Institutes of Health research project grant inflation 1998 to 2021.1998 年至 2021 年期间,美国国立卫生研究院研究项目资助膨胀。
Elife. 2023 Feb 10;12:e84245. doi: 10.7554/eLife.84245.
3
Ordering CT pulmonary angiography to exclude pulmonary embolism: defense versus evidence in the emergency room.在急诊室中,为排除肺栓塞而行 CT 肺动脉造影检查:证据与辩护。

本文引用的文献

1
Effect of two intensive statin regimens on progression of coronary disease.两种强化他汀类药物治疗方案对冠状动脉疾病进展的影响。
N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15.
2
Long interdialytic interval and mortality among patients receiving hemodialysis.长透析间期与血液透析患者的死亡率。
N Engl J Med. 2011 Sep 22;365(12):1099-107. doi: 10.1056/NEJMoa1103313.
3
A step toward personalized asthma treatment.迈向个性化哮喘治疗的一步。
Intensive Care Med. 2012 Aug;38(8):1345-51. doi: 10.1007/s00134-012-2595-z. Epub 2012 May 15.
N Engl J Med. 2011 Sep 29;365(13):1245-6. doi: 10.1056/NEJMe1102469. Epub 2011 Sep 26.
4
Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma.GLCCI1 基因与哮喘患者糖皮质激素治疗反应的全基因组关联研究。
N Engl J Med. 2011 Sep 29;365(13):1173-83. doi: 10.1056/NEJMoa0911353. Epub 2011 Sep 26.
5
Health care system delay and heart failure in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: follow-up of population-based medical registry data.在接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中,医疗保健系统延迟与心力衰竭:基于人群的医学登记数据随访。
Ann Intern Med. 2011 Sep 20;155(6):361-7. doi: 10.7326/0003-4819-155-6-201109200-00004.
6
Stenting versus aggressive medical therapy for intracranial arterial stenosis.颅内动脉狭窄的血管内支架置入与积极药物治疗的比较。
N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7.
7
Primum non nocere.首要的是不伤害。
Ann Intern Med. 2011 Sep 6;155(5):329-30. doi: 10.7326/0003-4819-155-5-201109060-00012.
8
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.盎格鲁-斯堪的纳维亚心脏结局试验(ASCOT):英国降脂治疗臂 11 年死亡率随访结果
Eur Heart J. 2011 Oct;32(20):2525-32. doi: 10.1093/eurheartj/ehr333. Epub 2011 Aug 28.
9
A new era for anticoagulation in atrial fibrillation.心房颤动抗凝治疗的新时代。
N Engl J Med. 2011 Sep 15;365(11):1052-4. doi: 10.1056/NEJMe1109748. Epub 2011 Aug 27.
10
Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis.罪犯血管血运重建与多血管病变和分期经皮冠状动脉介入治疗 ST 段抬高型心肌梗死患者多血管病变的比较:一项基于成对和网络荟萃分析。
J Am Coll Cardiol. 2011 Aug 9;58(7):692-703. doi: 10.1016/j.jacc.2011.03.046.